

Genetic Reports Abstracts

Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease

Manu Sharma^{a,b,*}, Demetrius M. Maraganore^c, John P.A. Ioannidis^{d,e}, Olaf Riess^f, Jan O. Aasly^g, Grazia Annesi^h, Nadine Abahuniⁱ, Anna Rita Bentivoglio^j, Alexis Brice^k, Christine Van Broeckhoven^{l,m}, Marie-Christine Chartier-Harlinⁿ, Alain Destéeⁿ, Ana Djarmati^o, Alexis Elbaz^p, Matthew Farrer^q, Carlo Ferrarese^r, J. Mark Gibson^{s,t}, Suzana Gispertⁱ, Nobutaka Hattori^u, Barbara Jasinska-Myga^v, Christine Klein^o, Suzanne Lesage^k, Timothy Lynch^{s,t}, Peter Lichtner^w, Jean-Charles Lambert^x, Anthony E. Lang^y, George D. Mellick^{z,aa}, Francesa De Nigris^j, Grzegorz Opala^v, Aldo Quattrone^{bb}, Chiara Riva^r, Ekaterina Rogaeva^{cc}, Owen A. Ross^{dd}, Wataru Satake^{ee}, Peter A. Silburn^{z,aa}, Jessie Theuns^{l,m}, Tatsushi Toda^{dd}, Hiroyuki Tomiyama^t, Ryan J. Uitti^{ff}, Karin Wirdefeldt^{gg}, Zbigniew Wszolek^{ff}, Thomas Gasser^{a,b}, Rejko Krüger^{a,b}, for the Genetic Epidemiology of Parkinson's Disease Consortium

^a Center of Neurology and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tuebingen, Germany

^b DZNE-German Centre for Neurodegenerative Diseases, Tuebingen, Germany

^c Department of Neurology North Shore University Health System, IL, USA

^d Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece

^e Stanford Prevention Research Centre, Stanford, CA, USA

^f Department of Medical Genetics, University of Tübingen, Germany

^g Department of Neurology, St. Olav's hospital and NTNU, Trondheim, Norway

^h Institute of Neurological Sciences, National Research Council, Cosenza, Italy

ⁱ Department of Neurology, Goethe University, Frankfurt am Main, Germany

^j Department of Neurology, Catholic University, Rome, Italy

^k INSERM, UMR_S975, Université Pierre et Marie Curie-Paris, CNRS, UMR 7225, AP-HP, Pitié-Salpêtrière Hospital, Paris, France

^l Laboratory of Neurogenetics, Institute Born-Bunge, University of Antwerp, Antwerpen, Belgium

^m Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, VIB, Antwerpen, Belgium

ⁿ Inserm UMR837, Centre de Recherche JPArc, Service de Neurologie et de Pathologie du Mouvement CHRU de Lille, University Lille Nord de France

^o Section of Clinical and Molecular Neurogenetics at the Department of Neurology, University of Lübeck, Germany

^p INSERM, Unit 708, F-75013, Paris, France and UPMC Univ Paris 06, U708, Neuroepidemiology, F-75005, Paris, France

^q Department of Genetics, University of British Columbia, Vancouver, BC, Canada

^r Department of Neuroscience-Section of Neurology, University of Milano-Bicocca San Gerardo Hospital, Monza, Italy

^s The Dublin Neurological Institute at the Mater Misericordiae University Hospital, and Conway Institute, University College Dublin, Ireland

^t Department of Neurology, Royal Victoria Hospital, Belfast, Ireland

^u Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan

^v Department of Neurology, Medical University of Silesia, Katowice, Poland

^w Helmholtz Zentrum München, German Research Centre for Environmental Health (GmbH), Neuherberg, Germany

^x INSERM U744, Institut Pasteur de Lille, Université Lille Nord de France, UDSL, Lille, France

^y Movement Disorders Centre, Toronto Western Hospital, University of Toronto, Toronto, Canada

^z Eskitis Institute for Cell and Molecular Therapies, Griffith University, Nathan, QLD, Australia

^{aa} University of Queensland, Centre for Clinical Research, Royal Brisbane Hospital

^{bb} Institute of Neurology, University Magna Graecia, Catanzaro, Italy

^{cc} Tanz Centre for Research in Neurodegenerative Diseases, Department of Medicine, University of Toronto, Toronto, Canada

^{dd} Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA

^{ee} Division of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Japan

^{ff} Department of Neurology, Mayo Clinic, Jacksonville, FL, USA

^{gg} Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

Received 23 December 2010; received in revised form 15 April 2011; accepted 30 May 2011

Abstract

Sepiapterin reductase (*SPR*) gene is an enzyme which catalyses the final step of tetrahydrobiopterin synthesis (BH4) and was implicated in Parkinson's disease (PD) pathogenesis as a candidate gene for PARK3 locus. A number of studies yielded association of the PARK3 locus with PD, and *SPR* knockout mice were shown to display parkinsonian features. To evaluate the role of *SPR* gene polymorphisms in diverse populations in PD, we performed collaborative analyses in the Genetic Epidemiology of Parkinson Disease (GEO-PD) Consortium. A total of 5 single nucleotide polymorphisms (3 in the promoter region and 2 in the 3' untranslated region [UTR]) were genotyped. Fixed as well as random effect models were used to provide summary risk estimates of *SPR* variants. A total of 19 sites provided data for 6547 cases and 9321 controls. Overall odds ratio estimates varied from 0.92 to 1.01. No overall association with the *SPR* gene using either fixed effect or random effect model was observed in the studied population. I^2 Metric varied from 0% to 36.2%. There was some evidence for an association for participants of North European/Scandinavian descent with the strongest signal for rs1876487 (odds ratio = 0.82; p value = 0.003). Interestingly, families which were used to map the PARK3 locus, have Scandinavian ancestry suggesting a founder effect. In conclusion, this large association study for the *SPR* gene revealed no association for PD worldwide. However, taking the initial mapping of the PARK3 into account, the role of a population-specific effect warrants consideration in future studies.

© 2011 Elsevier Inc. All rights reserved.

Keywords: Parkinson disease; *SPR*; PARK3; PD genetic studies; PD-GWAS

1. Introduction

We performed a large multicenter collaborative study among the Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium sites to assess the world-wide the role of common variation in the *SPR* gene in Parkinson's disease (PD). This large study includes over 15,868 subjects from 19 sites representing 14 countries from 4 continents (supplementary material).

2. Methods

A total of 19 teams representing 14 countries and 4 continents agreed to participate and contributed clinical and genotypic data for a total of 15,868 individuals (6547 cases and 9321 controls). A total of 5 single nucleotide polymorphisms (SNPs) were selected for genotyping: rs1396107, rs1567230, rs2421095, rs1876487, and rs1561244 listed in order from 5' to 3' end of the gene (Karamohamed et al., 2003; Sharma et al., 2006) (supplementary material).

3. Results

Nineteen sites contributed 6547 cases and 9321 controls. Characteristics of all participating sites are shown in Table 1 (supplementary material). The distribution of allele frequencies of each SNP per site is shown in Supplementary Table 2. The meta-analysis did not reveal nominal significant associations either by random or fixed effect models, with the tentative exception of rs1876487. The summary odds ratio (OR) for rs1876487 was 0.95 (95% confidence

interval, 0.89–1.00) with a p value of 0.05, uncorrected for multiple testing (Table 1 and supplementary material).

4. Discussion

This very large association study of common variants in the *SPR* gene with PD has revealed no evidence of association world-wide and it excludes large effects for any of the tested variants (supplementary material). Although most genetic association studies typically consider all European populations to share some common ancestry, a recent study established direct correlation between genetic makeup and the geographic location from which samples are ascertained within the European continent. This has also been shown in PD genetics, where in a recently published Genome-Wide Association Study (GWAS) on PD the authors observed a frequency gradient and differential genetic impact for SNP rs3129882 within European population for human leukocyte antigen (HLA) locus (supplementary material). Thus it is conceivable that rs1876487 and/or rs1567230 ($D' = 1.0$; $r^2 = 0.29$) may modulate the disease susceptibility only in populations from Northern European descent. Furthermore, haplotype analysis restricted to North European population showed suggestive evidence of association for haplotype (rs2421095-rs1876487-rs1561244; odds ratio, 0.57; p -value 0.07), again suggesting the role of founder effect for PARK3 locus in North European/Scandinavian populations. Acknowledging these caveats, our study is large enough to suggest that these variants are unlikely to be a clinically important determinant of PD risk world-wide and future efforts should focus specifically on Northern European populations.

Disclosure statement

All authors have reported no actual or potential conflict of interest.

* Corresponding author at: Hertie-Institute of Clinical Brain Research, Department of Neurology, University of Tuebingen, Hoppe-Seyler-Str. 3, 72076 Tuebingen, Germany. Tel.: +49 7071 29 81 968; fax: +49 7071 29 4620.

E-mail address: manu.sharma@uni-tuebingen.de (M. Sharma).

Download English Version:

<https://daneshyari.com/en/article/6810225>

Download Persian Version:

<https://daneshyari.com/article/6810225>

[Daneshyari.com](https://daneshyari.com)